Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 108

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 108
---
 or those countries shall be deemed
a license to the Know-How during such post-expiration period.

Either LipoVation or Yissum may terminate the
agreement immediately upon written notice to the other relating to bankruptcy and insolvency matters, upon 90 days’ written notice
of a material breach if such breach is not cured, and upon 90 days with notice of a non-material breach, is such breach is not cured.
Notwithstanding the foregoing, a party is entitled to an extra 45 days to cure a breach if the breach is not capable of cure during the
stated period if the breaching party uses diligent good faith efforts to cure the breach. In addition, Yissum may terminate the agreement
(a) immediately if an attachment is made over our assets and/or execution proceedings are taken against us and are not set aside within
60 days of the date of attachment or proceedings, as applicable and (b) if we fail to pay, in full, the research fee under a related sponsored
research agreement upon 45 days’ notice, subject to certain exceptions. We may terminate the license agreement for any reason on
30 days’ prior written notice to Yissum.

Termination of the agreement will result in the
termination of the license and, accordingly, the Licensed Technology and all rights included therein will revert to Yissum. All sublicenses
under the agreement are required to provide that, upon termination of the license, in whole or in part, that is, with respect to any country,
the sublicense shall terminate; provided that as long as the sublicensee is not in breach of the sublicense agreement at such time to
the extent that we would have the right to terminate the sublicense, Yissum will be required to act in one of the two following ways:
either (a) enter into a new agreement with the sublicensee upon substantially the same terms as the sublicense as long as the terms are
amended such that Yissum is not subject to any obligation or liability which are not included in, or in greater scope than, Yissum’s
obligations or liabilities under the license agreement; or (b) require the sublicensee to enter into a new license agreement on substantially
the same terms and conditions as those contained in the license agreement.

<div align='center'>66</div>

We have the first right to prepare, file, prosecute
and maintain any patent applications and patents in respect of the licensed technology and any part thereof, at our expense, subject to